Repaglinide
Back to searchMolecule Structure
Scientific Name
Repaglinide
Description of the Drug
Repaglinide is a antihyperglycemic used to improve glycemic control in diabetes.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00912
http://www.drugbank.ca/drugs/DB00912
Brand Name(s)
Enyglid, Novonorm, Prandin, Repaglinide
Company Owner(s)
Padagis Us Llc, Novo Nordisk Inc, Sun Pharmaceutical Industries Inc, Actavis Totowa Llc, Chartwell Rx Sciences Llc, Boscogen Inc, Aurobindo Pharma Ltd, Gemini Laboratories Llc, Mylan Pharmaceuticals Inc, Lupin Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sulfonylurea receptor 1, Kir6.2 | PROTEIN COMPLEX | BLOCKER | CHEMBL2096972 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL16137 | |
| PharmGKB | PA451234 | |
| Human Metabolome Database | HMDB0015048 | |
| DrugBank | DB00912 | |
| PubChem: Thomson Pharma | 14833410 | 14808699 |
| PubChem | 65981 | |
| Mcule | MCULE-3611790330 | |
| NMRShiftDB | 70020499 | |
| LINCS | LSM-3863 | |
| Nikkaji | J555.407A | |
| PDBe | BJX | |
| BindingDB | 50153520 | |
| EPA CompTox Dashboard | DTXSID3023552 | |
| DrugCentral | 2366 | |
| Brenda | 145071 | 145985 |
| ChemicalBook | CB4140539 | |
| Guide to Pharmacology | 6841 | |
| rxnorm | REPAGLINIDE | PRANDIN |
| PubChem: Drugs of the Future | 12014667 | |
| KEGG Ligand | C07670 | |
| ChEBI | 8805 | |
| ZINC | ZINC000003798537 |
